AcelRx Pharmaceuticals Inc expected to post a loss of 8 cents a share - Earnings Preview

Talphera

13/08/2021 21:00

* AcelRx Pharmaceuticals Inc  ACRX.OQ   ACRX.O  is expected
to show a fall in quarterly revenue when it reports results on
August 16. 
* The Hayward, California-based company is expected to report 
 a 38.1% decrease in revenue to $1.809 million from $2.92
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for AcelRx Pharmaceuticals
Inc is for a loss of 8 cents per share. For the same quarter
last year, the company reported a loss of 8 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for AcelRx
Pharmaceuticals Inc is $7​, about 83% above​ its last closing
price of $1.19. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.08       -0.08      -0.08     Met     4
 Dec. 31 2020  -0.12       -0.10      -0.10     Met     3.2
 Sep. 30 2020  -0.08       -0.08      -0.10     Missed  -21.2​
 Jun. 30 2020  -0.12       -0.14      -0.08     Beat    41.8
 Mar.          -0.17​      -0.17      -0.20     Missed  -17.6​
 31​ 2020​                                              
 Dec. 31 2019              -0.20      -0.18     Beat    8.5​
 Sep. 30 2019  -0.21       -0.22      -0.16     Beat    28.1
 Jun. 30 2019  -0.22       -0.22      -0.16     Beat    27
 This summary was machine generated August 13 at 20:00 GMT.  All
figures in US dollars unless otherwise stated